Avastin is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Bevacizumab.
| Product ID | 50242-060_3580958a-7a01-45c0-8d9c-87d9a3963158 | 
| NDC | 50242-060 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Avastin | 
| Generic Name | Bevacizumab | 
| Dosage Form | Injection, Solution | 
| Route of Administration | INTRAVENOUS | 
| Marketing Start Date | 2004-02-26 | 
| Marketing Category | BLA / BLA | 
| Application Number | BLA125085 | 
| Labeler Name | Genentech, Inc. | 
| Substance Name | BEVACIZUMAB | 
| Active Ingredient Strength | 100 mg/4mL | 
| Pharm Classes | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2023-12-31 | 
| Marketing Start Date | 2004-02-26 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | BLA | 
| Application Number | BLA125085 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | ML | 
| Marketing Start Date | 2019-04-01 | 
| Marketing Category | BLA | 
| Application Number | BLA125085 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | ML | 
| Marketing Start Date | 2004-02-26 | 
| Ingredient | Strength | 
|---|---|
| BEVACIZUMAB | 100 mg/4mL | 
| SPL SET ID: | 939b5d1f-9fb2-4499-80ef-0607aa6b114e | 
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 50242-060 | Avastin | bevacizumab | 
| 50242-061 | Avastin | bevacizumab | 
Mark Image Registration | Serial  | Company  Trademark Application Date  | 
|---|---|
![]() AVASTIN  76278294  2981298 Live/Registered  | 
        GENENTECH, INC.  2001-06-29  |